17 results about "Lyso-" patented technology

The invention discloses a preserving fluid for stably preserving sample DNA at normal temperature and a preparation method thereof, and belongs to the technical field of biological sample preservation. The preserving fluid comprises a lysis system, a nucleic acid protection system and a buffering and stabilizing system, the cracking system comprises a composite surfactant and an enzymolysis auxiliary agent; the composite surface active agent is prepared from polyether polyol fatty acid ester and cocamidopropyl hydroxy sulfobetaine; the enzymolysis auxiliary agent comprises lysozyme Lyso-V and protease K; the nucleic acid protection system comprises a nitrogen heterocyclic polyamine-carboxylic acid derivative and dextran sulfate; the nitrogen heterocyclic polyamine-carboxylic acid derivative comprises 1, 4, 7, 10-tetraazacyclododecane-N, N ', N' ', N ''tetraacetic acid, 1, 4, 7-triazacyclononane-N, N', N''-triacetic acid, disodium ethylene diamine tetraacetate-nitrogen heterocyclic derivative, and diethylenetriamine pentaacetic acid-piperazine derivative, and the nitrogen heterocyclic polyamine-carboxylic acid derivative comprises 1, 4, 7, 10-tetraazacyclododecane-N, N ', N '', N'' tetraacetic acid, 1, 4, 7-triazacyclononane-N, N', N ''-triacetic acid. The buffering and stabilizing system comprises an amphoteric buffering agent and a polymer stabilizer; the amphoteric buffering agent comprises 2-(N-morpholino) ethanesulfonic acid and N-tri (hydroxymethyl) methylglycine.

The invention provides an L-lysine production strain as well as a strain construction method and application. A hom (V59A) is introduced on a genome by utilizing a homologous recombination gene editing technology to weaken a competitive approach of lysine; the lysC (T311I) which is not inhibited by L-lysine is overexpressed; the method comprises the following steps of: overexpressing lysE, lysA, ddh, dapB and asd, knocking out a lysI gene and multi-copying the lysE, carrying out synchronous multi-copying on the dapA and EcdapB genes through a manual operon P1676-EcdapB-Pa12-dapA, and carrying out synchronous multi-copying on the dapB, ddh, lysA and lysO genes through a manual operon Psod-dapB-ddh-Ptuf-lysO-lysA; the constructed strain does not contain plasmids, has no defects, does not need induction, has the advantages of good genetic stability, high fermentation yield and the like, and can be used for stably producing L-lysine.

The invention discloses a high-load transparent rare earth complex organic glass scintillator as well as a preparation method and application thereof. The scintillator comprises a polymer matrix and an ionic rare earth complex dispersed in the polymer matrix, the rare earth complex comprises coordination anions and ionic liquid cations, the coordination anions comprise rare earth ions and organic ligands, and the loading capacity of the rare earth complex in the polymer matrix can reach 80-90 wt%. According to the scintillator, an ionic liquid is introduced to construct an ionic supramolecular structure, effective isolation of a luminescence center is realized by utilizing steric hindrance and a charge shielding effect, concentration quenching is inhibited, and compatibility with a matrix is enhanced, so that the material still keeps transparency of 90% or above under an ultrahigh load. The maximum radiation luminous intensity of the scintillator is 23.9 times that of commercial LYSO, the lower detection limit is as low as 56nGy / s, and the scintillator is suitable for the fields of high-energy particle detection, X-ray imaging and the like.

The invention discloses a synthesis method of a DOTAP (3, 4-Dimethyl-1, 3-pentanedione) dissolved blood lipid. Specifically, the invention provides a synthetic method of a compound as shown in a formula I. The synthetic method is characterized by comprising the following steps: 1, in an organic solvent and in the presence of alkali and a fluorine source, carrying out deprotection reaction on a compound as shown in a formula A4, carrying out quenching reaction by using solid alkali, and recrystallizing to obtain the compound as shown in the formula I; the fluorine source is hydrogen fluoride or hydrogen fluoride salt; the recrystallization solvent is a ketone solvent and an alcohol solvent. The synthetic method disclosed by the invention has relatively high yield and purity, and the conversion from the Lyso-DOTAP-1 to the Lyso-DOTAP-2 in the synthetic process is avoided to a great extent.

Provided are compositions and methods for reducing pre-existing antibodies against viral vector or gene-editing related proteins. The compositions showed reduction in various antibody titers by administration of a liposome composition complexed with a protein or fragment thereof of a viral vector. The liposomes comprise phosphatidylcholine and phosphatidylserine, wherein some or all of the PS is present as lyso-PS. The compositions and methods can be used in conjunction with gene therapy and nucleic acid based vector based vaccinations and therapeutics.

The invention relates to the non-therapeutical use of phosphatidylcholine and / or lyso- phosphatidylcholine for increasing the nutrient retention of at least one Long-Chain Fatty Acid (LCFA) in an animal or a human, or to a use of phosphatidylcholine and / or lyso- phosphatidylcholine for increasing the thermal stability of at least one Long-Chain 5 Unsaturated Fatty Acid (LC-UFA). The invention further relates to an ingestible composition, and a method of preparation of such a composition.

This invention discloses a preservation solution for preserving sample DNA at room temperature and its preparation method, belonging to the field of biological sample preservation technology. The preservation solution comprises: a lysis system, a nucleic acid protection system, and a buffering and stabilizing system; the lysis system comprises a complex surfactant and an enzymatic hydrolysis aid; the complex surfactant comprises: polyether polyol fatty acid ester and cocamidopropyl hydroxysulfonate betaine; the enzymatic hydrolysis aid comprises lysozyme Lyso-V and proteinase K; the nucleic acid protection system comprises: nitrogen-heterocyclic polyamine-carboxylic acid derivatives and dextran sulfate; the nitrogen-heterocyclic polyamine-carboxylic acid derivatives comprise: 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''tetraacetic acid, 1,4,7-triazacyclononane-N,N',N''-triacetic acid, disodium ethylenediaminetetraacetate-nitrocyclic derivative, and diethylenetriaminepentaacetic acid-piperazine derivative; the buffering and stabilizing system comprises: an amphoteric buffer and a polymeric stabilizer; the amphoteric buffer comprises: 2-(N-morpholino)ethanesulfonic acid and N-tris(hydroxymethyl)methylglycine.

A method for quantifying Hex4, lyso-GM1, Fuc-GlcNAc-Asn, or lyso-sulfatide included in cerebrospinal fluid, the method including adding an internal standard substance to a solution including the cerebrospinal fluid, submitting the solution including the cerebrospinal fluid, to which the internal standard substance has been added, to liquid chromatography to obtain an eluate, and subjecting the eluate to mass analysis.

The invention discloses a liposome nanoparticle in-vitro release medium and an in-vitro release test method. The liposome nanoparticle in-vitro release medium comprises the following components: a buffer solution and lipid, wherein the lipid is one or more of DOPE and at least one of DOPS, POPS, DOPC, DSPC, Egg PC, Lyso PC, DPPC, DPPE, DMPE, POPE, DOPG and DGPG. The liposome nanoparticle in-vitro release medium simulates an in-vivo environment in vitro, and an in-vitro release curve is drawn by detecting the contents of nucleic acid, polypeptide and antibody, so that the liposome nanoparticle in-vitro release medium has important significance on prescription development and quality research of liposome nanoparticles.

This invention discloses a method for determining related substances in liposome adjuvants and its applications, relating to the field of pharmaceutical testing. The method is a high-performance liquid chromatography (HPLC) method. Mobile phase A comprises an aqueous solution containing trifluoroacetic acid; mobile phase B comprises a mixed solution of methanol and acetonitrile containing trifluoroacetic acid. Through a specific elution procedure, the simultaneous detection of multiple target substances in liposome adjuvants is achieved, including oleic acid, ketocholesterol, two isomers of Lyso-DOTAP, and two isomers of Lyso-DOPC. This method exhibits good specificity, high sensitivity, and good resolution, providing a new approach for evaluating the efficacy, safety, and stability of liposome adjuvants.

The present invention relates to: a biomarker composition for diagnosing multiple cancers, the biomarker composition comprising metabolites; and an artificial intelligence-based method for providing information for diagnosing multiple cancers and, more specifically, to a biomarker composition for diagnosing multiple cancers and an artificial intelligence-based method for providing information for diagnosing multiple cancers, the biomarker composition comprising at least five biomarkers selected from the group consisting of valine (Val), glutamate (Glu), N-methyl-2-pyridone-5-carboxamide (2PY), tryptophan (Trp), kynurenine (KN), acetylcarnitine (AC), hexanoylcarnitine (HC), octanoylcarnitine (OC), decanoylcarnitine (DC), lauroylcarnitine (LAC), myristoylcarnitine (MC), palmitoylcarnitine (PC), 16:0 Lyso PC (LPC16), 18:0 Lyso PC (LPC18), 15:0-18:1 PC (15PC), 16:0 SM (16SM), 18:1 SM (18SM), and 24:1 SM (24SM).

The present invention provides methods for detecting multiple biomarkers indicative for lysosomal storage diseases from a dried blood spot. In particular, the present invention provides a method that is suited for detecting multiple biomarkers, each indicative for the presence of a distinct lysosomal storage disease in a subject, based on a single sample preparation procedure. In particular, the method allows simultaneous extraction of different biomarkers such as Lyso-Gb1 (GlcSph). Lyso-Gb3, and others from a dried blood spot sample. The invention further provides a kit of parts comprising means for conducting the methods subject of the invention. Finally, the invention provides a set of reference ranges for Lyso-Gb1 (GlcSph) and Lyso-Gb3 in healthy subjects starting from dried blot spot samples.

Provided are a composition containing a lipid nanoparticle (LNP) and an mRNA, and use thereof in the treatment of Gaucher disease. The composition contains an LNP and an mRNA, and the mRNA is encapsulated in the LNP or associated with the LNP, wherein the mRNA contains a nucleotide sequence encoding GBA1. The composition can effectively increase the expression and activity of β-glucocerebrosidase (β-GCase) in the serum and multiple target organs of a subject, and reduce the level of glucosylsphingosine (Lyso-GL1) therein. In addition, the composition possesses a relatively long half-life and has application prospects in the treatment of Gaucher disease.

The invention discloses an application of lysolecithin in preparation of a product for protecting immune stress of pigs, the body health of the pigs in an immune stress scene can be protected by feeding the pigs with the product containing the lysolecithin, and the damage of intestinal tracts and livers of the pigs caused by lipopolysaccharide stimulation can be relieved, so that the immune stress of the pigs can be protected. The purpose of preventing the pig intestinal injury and / or liver injury can be achieved, the purpose of treating the pig intestinal injury and / or liver injury can also be achieved, and the pig intestinal injury and / or liver can be protected.

Disclosed are methods of preparing liposomes without size exclusion steps resulting in small sized liposomes exhibiting narrow size distribution and compositions of same. The methods utilize liposome formation from lyso-PS, PS, and PC as the only phospholipids.

The application provides a lysophosphatidylcholine (LPC) kit with anti-coccidiosis effect, and discloses a diagnosis marker for Eimeria tenella infected chicken, which is characteristic phospholipid and sphingolipid molecules, and specifically phosphatidylcholine (PC), lysophosphatidylcholine (LPC) and sphingomyelin (SM). Meanwhile, the application provides a medicine composition for improving the survival rate of chicks infected with Eimeria tenella, which is characterized by containing effective amounts of 18:2 LPA, 18:1 LPC, 22:0 LPC, 16:0 18:1 PC, 16:0 18:2 PC and d18:1 16:0 SM. The application screens characteristic phospholipid and sphingolipid molecules in the cecum tissue of chicken infected with Eimeria tenella for the first time, and verifies the curative effect of phosphatidylcholine (PC), lysophosphatidylcholine (LPC) and sphingomyelin (SM) on acute infection of chicks with Eimeria tenella, which has great market development prospect.

The present invention relates to a method for increasing production of a lyso-ornithine lipid in a microorganism, by expressing a heterologous ornithine acyl-ACP N-acyltransferase and elevating levels of an acyl carrier protein in the microorganism. Also provided for is a method of obtaining lyso-ornithine lipids with differing fatty acid chain lengths by varying the ornithine concentration. The invention further provides for recombinant microorganisms capable of producing increased levels of a lyso-ornithine lipid, which is useful as a biosurfactant. Also provided are lyso-ornithine lipids produced by the method or by the recombinant microorganism and application thereof as a biosurfactant.